Talimogene Laherparepvec
Amgen
['melsm', 'melanoma']
5-year follow-up shows neoadjuvant t-vec benefit in patients with resectable melanoma #melanoma #melsm #oncology #nursing #esmo22 
Your online destination for Oncology Nursing news, clinical insights, and resources.